Article
BRAF inhibitor therapy in HCL.
Best practice & research. Clinical haematology - 1 Dec 2015
Dietrich Sascha, Zenz Thorsten
Abstract excerpt
Targeted treatment approaches are transforming the therapeutic landscape of cancer care. The discovery of the BRAF V600E mutation in most cases of classical hairy cell leukemia opens up unique opportunities for tumor specific treatment of HCL targeting the MEK/ERK signaling pathway. The discovery and biological implications of BRAF V600E in HCL are summarized to form a basis for our current understanding of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
